This study is for people with type 2 diabetes, which is when your body has trouble using sugar the right way. The study will test a new medicine called CagriSema to see if it helps lower blood sugar and weight. CagriSema will be compared to another medicine, tirzepatide, which is already used in some countries. Participants will be randomly assigned to receive either CagriSema or tirzepatide, much like flipping a coin. The study will last up to one and a half years.

To join, you need to be at least 18 years old, have type 2 diabetes for at least 180 days, and be on a stable dose of metformin with or without an SGLT2 inhibitor for at least 90 days. Your blood sugar levels should be within certain limits, and your body mass index (BMI) must be 30 or higher. Certain conditions, like pregnancy or severe kidney problems, will prevent you from joining.

• The study duration is up to 1.5 years.
• You'll be assigned a treatment randomly.
• Participants must be on specific diabetes medications.